A Phase 3 interventional study of Azilsartan medoxomil with or without add-on chlorthalidone and Azilsartan medoxomil with or without add-on hydrochlorothiazide in Hypertension, sponsored by Takeda. Completed at 41 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-19.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing azilsartan medoxomil in Essential Hypertension — none open to participants now, none under way, none of them phase 3. azilsartan medoxomil · Essential Hypertension.
Among the 11 studies testing azilsartan medoxomil in Essential Hypertension, this one is the 7th largest by enrollment, is one of 3 that started in 2007, is one of 10 in phase 3, and was the 1st registered.
480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.
Browse Essential Hypertension studies →None of the 11 studies testing azilsartan medoxomil in Essential Hypertension is open now. The open studies under Essential Hypertension, anywhere →
azilsartan medoxomil: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2007.
This study's enrollment of 669 is above the median of 144 across 407 interventional studies indexed under Essential Hypertension.
Median enrollment 837 across the 11 interventional studies. Of the 11 that completed or were terminated, 11 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 1 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
15 studies in Essential Hypertension by Takeda: none open now, none under way, none of them phase 3. Of 15 finished, 14 (93%) have results posted.
Among the 15 studies in Essential Hypertension by Takeda, this one is the 8th largest by enrollment, is one of 4 that started in 2007, is one of 12 in phase 3, and was the 1st registered.
Takeda’s Essential Hypertension studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing azilsartan medoxomil in Essential Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 15 in Essential Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This purpose of this study is to evaluate the long-term safety and tolerability of azilsartan medoxomil in individuals with essential hypertension.
Hypertension affects approximately 50 million individuals in the United States. As the population ages, the prevalence of hypertension will continue to increase if broad and effective preventive measures are not implemented. According to the World Health Organization, hypertension is the most common attributable cause of preventable death in developed nations, as uncontrolled hypertension greatly increases the risk of cardiovascular disease, cerebrovascular disease, and renal failure. Despite the availability of antihypertensive treatments, hypertension remains inadequately controlled; only about one-third of patients continue to maintain control successfully.
Takeda Global Research and Development is developing TAK-491 (azilsartan medoxomil) for the treatment of essential hypertension. This study is being conducted to demonstrate the long-term safety and tolerability of azilsartan medoxomil in individuals with essential hypertension.
Study participation is anticipated to be approximately 1 year and 1.5 months, and participants will be required to return to the clinic for 10 study visits.
480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.
This study's enrollment of 669 is above the median of 144 across 407 interventional studies indexed under Essential Hypertension.
Browse Essential Hypertension studies →Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Compared within Essential Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Azilsartan medoxomil with or without add-on chlorthalidone · Drug: Azilsartan medoxomil with or without add-on hydrochlorothiazide
Drug page: Azilsartan medoxomil
Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with chlorthalidone 25 mg, once-daily, if target blood pressure not achieved.
Also known as: TAK-491, Edarbi
Drug page: Azilsartan medoxomil
Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with hydrochlorothiazide 12.5 to 25 mg, once-daily, if target blood pressure not achieved.
Also known as: TAK-491, Edarbi
Number of Participants Reporting One or More Treatment-emergent Adverse Events From Day 1 Through End of the Study - Cohort 1.
Treatment-emergent adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 14 days after the last dose of study drug, or if a serious adverse event, within 30 days after the last dose of study drug.
Time frame: 56 weeks.
Number of Participants Reporting One or More Treatment-emergent Adverse Events From Day 1 Through End of the Study - Cohort 2.
Treatment-emergent adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 14 days after the last dose of study drug, or if a serious adverse event, within 30 days after the last dose of study drug.
Time frame: 56 weeks.
Change From Baseline in Sitting Clinic Systolic Blood Pressure - Cohort 1.
The change between sitting clinic systolic blood pressure measured at each week assessed relative to the baseline measurement. Mean calculated by using the average (arithmetic mean) of 3 measurements performed at each visit.
Time frame: 52 weeks
Change From Baseline in Sitting Clinic Systolic Blood Pressure - Cohort 2
The change between sitting clinic systolic blood pressure measured at each week assessed relative to the baseline measurement. Mean calculated by using the average (arithmetic mean) of 3 measurements performed at each visit.
Time frame: 52 weeks
Change From Baseline in Sitting Clinic Diastolic Blood Pressure - Cohort 1.
The change between sitting clinic diastolic blood pressure measured at each week assessed relative to the baseline measurement. Mean calculated by using the average (arithmetic mean) of 3 measurements performed at each visit.
Time frame: 52 weeks.
Change From Baseline in Sitting Clinic Diastolic Blood Pressure - Cohort 2.
The change between sitting clinic diastolic blood pressure measured at each week assessed relative to the baseline measurement. Mean calculated by using the average (arithmetic mean) of 3 measurements performed at each visit.
Time frame: 52 weeks.
Participants enrolled at 39 investigative sites in Chile, Mexico and the United States from 22 June 2007 to 30 April 2010.
| Milestone | Azilsartan Medoxomil |
|---|---|
| Started | 362 |
| Completed | 260 |
| Not completed | 102 |
| Withdrew: Adverse event | 26 |
| Withdrew: Protocol violation | 2 |
| Withdrew: Lost to follow-up | 30 |
| Withdrew: Withdrawal by subject | 25 |
| Withdrew: Lack of efficacy | 3 |
| Withdrew: Other | 16 |
| Milestone | Azilsartan Medoxomil |
|---|---|
| Started | 307 |
| Completed | 203 |
| Not completed | 104 |
| Withdrew: Adverse event | 24 |
| Withdrew: Protocol violation | 5 |
| Withdrew: Lost to follow-up | 38 |
| Withdrew: Withdrawal by subject | 28 |
| Withdrew: Lack of efficacy | 4 |
| Withdrew: Other | 5 |
Treatment-emergent adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 14 days after the last dose of study drug, or if a serious adverse event, within 30 days after the last dose of study drug.
| participants | Cohort 1 |
|---|---|
| Number of Participants | 267 |
| Percentage of Participants | 73.8 |
Treatment-emergent adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 14 days after the last dose of study drug, or if a serious adverse event, within 30 days after the last dose of study drug.
| participants | Cohort 2 |
|---|---|
| Number of Participants | 241 |
| Percentage of Participants | 78.5 |
The change between sitting clinic systolic blood pressure measured at each week assessed relative to the baseline measurement. Mean calculated by using the average (arithmetic mean) of 3 measurements performed at each visit.
| mmHg | Cohort 1 |
|---|---|
| Week 4 | -10.1 ± 15.21 |
| Week 8 | -13.1 ± 16.72 |
| Week 12 | -21.5 ± 15.80 |
| Week 16 | -25.4 ± 15.09 |
| Week 26 | -26.3 ± 15.97 |
| Week 36 | -27.3 ± 16.63 |
| Week 46 | -28.1 ± 17.21 |
| Week 56 | -25.2 ± 18.05 |
| Final Visit | -22.1 ± 18.64 |
The change between sitting clinic systolic blood pressure measured at each week assessed relative to the baseline measurement. Mean calculated by using the average (arithmetic mean) of 3 measurements performed at each visit.
| mmHg | Cohort 2 |
|---|---|
| Week 4 | -14.4 ± 13.57 |
| Week 8 | -17.5 ± 15.07 |
| Week 12 | -23.8 ± 15.97 |
| Week 16 | -26.2 ± 15.65 |
| Week 26 | -24.8 ± 15.25 |
| Week 36 | -22.5 ± 14.89 |
| Week 46 | -23.8 ± 15.35 |
| Week 56 | -24.2 ± 15.96 |
| Final Visit | -22.7 ± 17.14 |
The change between sitting clinic diastolic blood pressure measured at each week assessed relative to the baseline measurement. Mean calculated by using the average (arithmetic mean) of 3 measurements performed at each visit.
| mmHg | Cohort 1 |
|---|---|
| Week 4 | -8.9 ± 8.73 |
| Week 8 | -11.0 ± 9.97 |
| Week 12 | -15.9 ± 9.12 |
| Week 16 | -18.7 ± 9.06 |
| Week 26 | -18.6 ± 9.15 |
| Week 36 | -19.9 ± 9.13 |
| Week 46 | -19.8 ± 9.67 |
| Week 56 | -18.4 ± 9.52 |
| Final Visit | -16.5 ± 10.23 |
The change between sitting clinic diastolic blood pressure measured at each week assessed relative to the baseline measurement. Mean calculated by using the average (arithmetic mean) of 3 measurements performed at each visit.
| mmHg | Cohort 2 |
|---|---|
| Week 4 | -10.6 ± 9.23 |
| Week 8 | -12.3 ± 9.05 |
| Week 12 | -16.8 ± 9.48 |
| Week 16 | -18.2 ± 10.28 |
| Week 26 | -17.7 ± 10.95 |
| Week 36 | -16.2 ± 9.08 |
| Week 46 | -17.2 ± 9.57 |
| Week 56 | -17.9 ± 10.85 |
| Final Visit | -16.2 ± 11.05 |
Collected over Treatment-emergent adverse events (TEAEs) defined as any AEs, regardless of relationship to study drug, that occur after the first dose of study drug and within 14 days after last dose, or if an SAE, within 30 days after the last dose of study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 | — | 30/362 (8.3%) | 134/362 (37%) |
| Cohort 2 | — | 22/307 (7.2%) | 106/307 (34.5%) |
| Event | Cohort 1 | Cohort 2 |
|---|---|---|
| Chest painGeneral disorders | 1/362 | 2/307 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/362 | 2/307 |
| Coronary artery diseaseCardiac disorders | 2/362 | 0/307 |
| Syncope vasovagalNervous system disorders | 2/362 | 0/307 |
| AnaemiaBlood and lymphatic system disorders | 0/362 | 1/307 |
| Angina pectorisCardiac disorders | 0/362 | 1/307 |
| Atrial flutterCardiac disorders | 0/362 | 1/307 |
| Atrioventricular blockCardiac disorders | 0/362 | 1/307 |
| Myocardial infarctionCardiac disorders | 0/362 | 1/307 |
| TachycardiaCardiac disorders | 0/362 | 1/307 |
| Event | Cohort 1 | Cohort 2 |
|---|---|---|
| DizzinessNervous system disorders | 52/362 | 44/307 |
| HeadacheNervous system disorders | 38/362 | 28/307 |
| FatigueGeneral disorders | 32/362 | 16/307 |
| Urinary tract infectionInfections and infestations | 26/362 | 11/307 |
| Upper respiratory tract infectionInfections and infestations | 25/362 | 20/307 |
| Age, Customized(participants) | Azilsartan Medoxomil |
|---|---|
| <45 years (Cohort 1) | 81 |
| Between 45 and 64 years (Cohort 1) | 233 |
| ≥65 years (Cohort 1) | 48 |
| <45 years (Cohort 2) | 90 |
| Between 45 and 64 years (Cohort 2) | 193 |
| ≥65 years (Cohort 2) | 24 |
| Sex/Gender, Customized(participants) | Azilsartan Medoxomil |
|---|---|
| Female (Cohort 1) | 173 |
| Male (Cohort 1) | 189 |
| Female (Cohort 2) | 144 |
| Male (Cohort 2) | 163 |
The record gives a start of Jun 2007, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2011, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Azilsartan medoxomil